Amgen (AMGN) , along with Regeneron (REGN) announced Tuesday they have inked separate deals to expand their anti-cancer research programs. According to TheStreet's Adam Feuerstein, the new deals indicate a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth. Amgen is set to pay $65 million to license rights to a technology from Advaxis in order to develop immunotherapy treatments to help combat brain tumors. Meanwhile, the Regeneron partnership was signed with privately held Adicet Bio and aims to target blood cancers and solid tumors through a form of therapy similar to the those being developed by Juno Therapeutics and Kite Pharma.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.